Regulation of bacterial polysaccharide-specific B cell responses

细菌多糖特异性 B 细胞反应的调节

基本信息

  • 批准号:
    9329963
  • 负责人:
  • 金额:
    $ 40.47万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-08-22 至 2019-07-31
  • 项目状态:
    已结题

项目摘要

Vaccination induces immunological memory and is the most effective means of preventing infectious diseases. The magnitude and kinetics of anamnestic antibody responses is directly proportional to the quantity and quality of antigen-specific memory B cells. Host interactions with bacterial pathogens result in far more complex immune responses compared to isolated bacterial components that are commonly incorporated into vaccines. To understand the complexity of immune responses to whole bacteria we previously utilized a bacterial infection system and discovered a novel role for B1b cells. While the specific antigens driving the protective B cell responses in these bacterial systems have been identified, e.g. Vi polysaccharide (ViPS) of S. Typhi, the molecular mechanisms governing B cell memory to these T cell-independent antigens remains to be understood. It is known that re-immunization with purified polysaccharides including ViPS and PPS results in hyporesponsiveness, leading to serious concerns about the effectiveness of booster strategies that are currently in practice for such vaccines. More recently, PPS- and VIPS-conjugate vaccination strategy has failed to induce booster responses in disease endemic regions. We have previously hypothesized that efficient T cell- independent B cell responses require engagement with both B cell antigen receptor and co-stimulatory receptors such as Toll-like receptors. Indeed, we found that ViPS-expressing bacteria induce enhanced ViPS- specific secondary IgM and IgG responses compared to primary responses, which is indicative of PS-specific B cell memory. In striking contrast, secondary responses to Typhim Vi®, a vaccine composed of purified ViPS, severely impaired compared to the primary response indicating B cell hyporesponsiveness and the impact of this booster immunization strategy has never been determined in humans. S. Typhi is a human-restricted pathogen and does not productively infect commonly used inbred laboratory mice. This is a significant barrier to efforts to understand protective polysaccharide-specific memory responses against human typhoid. The S. Typhimurium infection system has been employed as a murine model of human typhoid. Using a novel chimeric strain of S. Typhimurium that was recently engineered to express surface characteristics of S. Typhi, we are able to demonstrate that the impairment in anti-VIPS responses correlates to more than an order of magnitude higher bacterial burden compared to whole bacterial immunization. Additionally, using a new and expansive panel of recombinant inbred mouse strains called the Collaborative Cross (CC) we have identified two independent CC mouse lines that can be productively infected with S. Typhi and develop histological features that are strikingly similar to biopsies taken from typhoid-infected humans. Preliminary results indicate that immunization of CC mice results in robust ViPS-specific antibody response. Collectively, these findings suggest that both the chimeric S. Typhimurium strain and CC mice can serve as novel in vivo translational platforms in which to assess the functional characteristics of polysaccharide-specific B cell responses.
接种疫苗可诱导免疫记忆,是预防传染病最有效的手段。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KISHORE R ALUGUPALLI其他文献

KISHORE R ALUGUPALLI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KISHORE R ALUGUPALLI', 18)}}的其他基金

A System to Study Salmonella Typhi Infection and Immunity
研究伤寒沙门氏菌感染和免疫的系统
  • 批准号:
    10361479
  • 财政年份:
    2021
  • 资助金额:
    $ 40.47万
  • 项目类别:
A System to Study Salmonella Typhi Infection and Immunity
研究伤寒沙门氏菌感染和免疫的系统
  • 批准号:
    10195207
  • 财政年份:
    2021
  • 资助金额:
    $ 40.47万
  • 项目类别:
Stem cell origins of human fetal/neonatal B cell subsets
人类胎儿/新生儿 B 细胞亚群的干细胞起源
  • 批准号:
    10159198
  • 财政年份:
    2020
  • 资助金额:
    $ 40.47万
  • 项目类别:
Induction of polysaccharide vaccine responses in the young by interleukin-7
白细胞介素7诱导年轻人多糖疫苗反应
  • 批准号:
    8638380
  • 财政年份:
    2014
  • 资助金额:
    $ 40.47万
  • 项目类别:
B1 cell-mediated immunity in Human Immune System mice
人类免疫系统小鼠中 B1 细胞介导的免疫
  • 批准号:
    8856488
  • 财政年份:
    2014
  • 资助金额:
    $ 40.47万
  • 项目类别:
Role of BAFFR in antigen-specific B1b cell persistence
BAFFR 在抗原特异性 B1b 细胞持久性中的作用
  • 批准号:
    8623197
  • 财政年份:
    2014
  • 资助金额:
    $ 40.47万
  • 项目类别:
B1 cell-mediated immunity in Human Immune System mice
人类免疫系统小鼠中 B1 细胞介导的免疫
  • 批准号:
    8747925
  • 财政年份:
    2014
  • 资助金额:
    $ 40.47万
  • 项目类别:
Induction of polysaccharide vaccine responses in the young by interleukin-7
白细胞介素7诱导年轻人多糖疫苗反应
  • 批准号:
    8786494
  • 财政年份:
    2014
  • 资助金额:
    $ 40.47万
  • 项目类别:
Toll-like receptor signaling in the generation of B1b cell memory
B1b 细胞记忆生成中的 Toll 样受体信号传导
  • 批准号:
    8524050
  • 财政年份:
    2012
  • 资助金额:
    $ 40.47万
  • 项目类别:
B1B lymphocytes generate T cell-independent memory
B1B 淋巴细胞产生不依赖于 T 细胞的记忆
  • 批准号:
    7261873
  • 财政年份:
    2006
  • 资助金额:
    $ 40.47万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 40.47万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 40.47万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 40.47万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.47万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 40.47万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 40.47万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 40.47万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 40.47万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 40.47万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 40.47万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了